NCT03075930

Brief Summary

This is a single centre prospective data registry. In this study atrial conduction characteristics of extended surface Electrocardiograms (esECG), biomarkers and genetic analysis will be performed before ablation, before discharge and 3 months after catheter ablation of atrial fibrillation (AF) and compared to routine clinical follow-up data. The objective of this registry is to establish a data registry of patients undergoing ablation of AF. Supplementary to the routine clinical diagnostic an esECG and an analysis of biomarkers will be performed and compared to clinical and outcome data.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,250

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 12, 2017

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 6, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 9, 2017

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2023

Completed
Last Updated

February 20, 2020

Status Verified

February 1, 2020

Enrollment Period

5 years

First QC Date

March 6, 2017

Last Update Submit

February 18, 2020

Conditions

Keywords

Atrial fibrillationECGBody surface potential mapRecurrence of AF

Outcome Measures

Primary Outcomes (1)

  • Recurrence of AF after ablation

    The predictive value for recurrence of AF in patients after ablation of AF based on atrial conduction characteristics in electrocardiographic, -anatomical, biomarker and genetic analysis

    12 months

Secondary Outcomes (3)

  • AF characteristics

    12 months

  • ECG AF characteristics

    3 months

  • ECG to BSPM discriminative power

    12 months

Study Arms (2)

Extended Electrocardiogram

Elective patients receiving an AF ablation receiving a extended ECG

Device: Extended Electrocardiogram

Body surface potential map

Elective patients receiving an AF ablation receiving a body surface potential map

Device: Body surface potential map

Interventions

ECG with 3 additional leads and a 5 minute recording

Extended Electrocardiogram

ECG with 184 leads and a 5 minute recording

Body surface potential map

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients referred for ablation of AF with a history of self-terminating or persistent non-valvular AF with at least one documented AF episode during the last 6 months

You may qualify if:

  • Documented self-terminating or persistent AF
  • Scheduled for ablation of AF
  • At least 18 years of age, mentally able and willing to give informed consent

You may not qualify if:

  • Emergency ablation
  • Serious patient condition before ablation
  • Physically or mentally unable to provide written informed consent
  • Permanent atrial fibrillation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maastricht University

Maastricht, Limburg, 6229HX, Netherlands

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Probes of blood for common gene variant analysis

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Laurent Pison, Physician

    Maastricht University

    STUDY DIRECTOR
  • Ulrich Schotten, Physician

    Maastricht University

    PRINCIPAL INVESTIGATOR
  • Matthias D Zink, Physician

    Maastricht University

    STUDY DIRECTOR

Central Study Contacts

Matthias D Zink, Physician

CONTACT

Ulrich Schotten, Physician

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 6, 2017

First Posted

March 9, 2017

Study Start

January 12, 2017

Primary Completion

January 1, 2022

Study Completion

January 1, 2023

Last Updated

February 20, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will share

This study is planned as a Single Center Study. But it could be possible to extend it to other centers. In this case data will be shared with the participating centers.

Shared Documents
STUDY PROTOCOL
Time Frame
In case of an extend to another participating center IPD are available for the collaborating center.
Access Criteria
In case of an extend to another participating center IPD are available for the collaborating center.

Locations